|
1 kits (10 Vials)
| Yawan: | |
|---|---|
▎ GLP-3 Bincike
Menene asalin bincike na GLP-3?
Kiba ya zama ɗaya daga cikin fitattun ƙalubalen lafiyar jama'a a cikin al'umma ta zamani. Yana iya haifar da matsalolin kiwon lafiya da yawa kamar nau'in ciwon sukari na 2, cututtukan zuciya, hauhawar jini, dyslipidemia, da cututtukan hanta mai ƙiba mara-giya. Tare da ci gaba da karuwa a cikin abubuwan da ke faruwa na kiba, ana ƙara buƙatar gaggawa don sababbin hanyoyin kwantar da hankali wanda zai iya sarrafa nauyin jiki yadda ya kamata da inganta yanayin kiwon lafiya [1] . Ko da yake sauye-sauyen salon rayuwa, irin su ƙara yawan motsa jiki da sarrafa abinci, sune ainihin matakan sarrafa nauyi, yana da matukar wahala ga yawancin manya masu kiba su kula da asarar nauyi na dogon lokaci.
GLP-3, a matsayin sabon agonist mai karɓa sau uku, na iya yin aiki akan mai karɓar glucagon-kamar peptide-1.
GLP-1R), mai karɓar mai karɓar insulinotropic polypeptide mai dogaro da glucose (GIPR), da mai karɓar glucagon (GCGR). Wannan tsarin aikin mai karɓa da yawa yana ba shi babban fa'ida a fagen asarar nauyi. Idan aka kwatanta da magungunan asarar nauyi waɗanda ke aiki akan mai karɓa ɗaya kawai, GLP-3 na iya ƙarin daidaita tsarin tafiyar da rayuwa ta jiki [1] . GLP-3 yana samun asarar nauyi ta hanyar daidaita masu karɓar hormone da yawa, ba wai kawai yana nuna ingantaccen tasiri ba har ma yana da ƙarancin illa na gastrointestinal. Bugu da kari, a matsayin agonist mai karɓar mai sau uku, GLP-3 yana da tasirin asarar nauyi mai ƙarfi da fa'ida na yawan jama'a idan aka kwatanta da sauran sabbin magungunan asarar nauyi.
Menene GLP-3?
GLP-3 labari ne mai tsayi mai tsayi glucagon-kamar peptide-1 (GLP-1) agonist mai karɓa. An gyara shi kuma an inganta shi bisa tsarin GLP-1 na halitta, kuma yana iya ɗaure musamman da kunna mai karɓar GLP-1, yana aiwatar da ayyukan physiological kama da na GLP-1 na halitta, kamar inganta haɓakar insulin, hana ƙwayar glucagon, jinkirta zubar da ciki, rage ci, da sauransu.
Menene tsarin aikin GLP-3?
Tsarin aikin GLP-3 ya samo asali ne daga tasirinsa na agonist akan masu karɓa da yawa. Da farko, tasirinsa na agonist akan mai karɓar glucagon-kamar peptide-1 (GLP-1R) na iya ƙara haɓakar insulin, hana ƙwayar glucagon, rage matakan glucose na jini, kuma a lokaci guda jinkirta ɓarna na ciki, ƙara yawan gamsuwa, da rage cin abinci [2] . Abu na biyu, tasirinsa na agonist akan mai karɓar insulinotropic polypeptide mai karɓa na glucose (GIPR) na iya haɓaka haɓakar insulin, haɓaka amfani da glucose, kuma yana tasiri metabolism mai mai, hana lipolysis da haɓaka haɓakar mai [2] . Haka kuma, tasirin agonist na GLP-3 akan mai karɓar glucagon (GCGR) yawanci yana haɓaka glycogenolysis da gluconeogenesis a cikin hanta, yana haɓaka matakan glucose na jini. Koyaya, a ƙarƙashin aikin GLP-3, wannan tasirin haɓakar glucose yana raguwa ta hanyar tasirin sauran masu karɓa guda biyu, yayin haɓaka lipolysis da rage yawan kitse [2] . Wannan yanayin aiki mai yawan manufa na iya zama mafi inganci wajen magance kiba fiye da agonists masu karɓa ɗaya.
Ta hanyar kunna waɗannan masu karɓa guda uku a lokaci guda, GLP-3 na iya yin tasiri iri-iri na tsarin rayuwa da kuma haifar da tasirin warkewa akan kiba da cututtukan da ke da alaƙa. Dangane da daidaita matakan glucose na jini, tunda kunna GLP-1R da GIPR suna haɓaka haɓakar insulin kuma yana hana ƙwayar glucagon, kuma kunna GCGR yana kashewa ta hanyar tasirin sauran masu karɓa guda biyu, GLP-3 na iya daidaita matakan glucose na jini yadda yakamata, wanda yake da mahimmanci ga jiyya na nau'in 22 metabolism [1, 1] . Dangane da rage yawan kitse, kunna GCGR yana haɓaka lipolysis kuma yana rage yawan kitse, yayin da kunna GLP-1R yana ƙaruwa da ƙima kuma yana rage cin abinci, yana ƙara rage haɓakar mai [1] . Bugu da ƙari, GLP-3 kuma yana da ingantaccen tasiri akan cututtukan hanta maras-giya. Yana iya rage kitsen da ke cikin hanta da inganta aikin hanta.
HbA1c, nauyin jiki, hawan jini, da lipids Bayanai sune mafi ƙanƙanta ma'anar murabba'i (tare da sandunan kuskure suna nuna SEs) daga saitin bincike na inganci, sai dai in an lura.
Source:PubMed [4]
A wanne bangare GLP-3 ke nuna tasirin sa?
GLP-3 yana nuna tasiri mai mahimmanci a fannoni da yawa
Mahimmin tasirin asarar nauyi: GLP-3 ya nuna tasirin asarar nauyi a cikin gwaje-gwajen asibiti da yawa. Misali, a cikin binciken asibiti da ya shafi manya 338 (Jastreboff AMM, 2023), marasa lafiya da aka yi musu magani tare da allurai daban-daban na GLP-3 sun sami babban asarar nauyi a makonni 48. Daga cikin su, marasa lafiya a cikin rukunin kashi na 12mg sun rasa 24.2% na nauyin jikinsu, kuma yawancin marasa lafiya sun sami asarar nauyi zuwa digiri daban-daban. Misali, tsakanin marasa lafiya da ke karbar 4mg, 8mg, da 12mg allurai, 92%, 100%, da 100% na marasa lafiya, bi da bi, sun rasa 5% ko fiye na nauyin jikinsu. A cikin wani binciken [3] , gwaje-gwaje guda biyu da aka bazu da suka hada da marasa lafiya 353 tare da nau'in ciwon sukari na 2 sun nuna cewa idan aka kwatanta da placebo, GLP-3 na iya rage nauyin jikin marasa lafiya da 11.89kg sosai, kuma yana rage haemoglobin glycated (HbA1C). Bugu da kari, a cikin gwaji na manya marasa lafiya tare da kiba ba tare da metabolism ba, GLP-3 ya haifar da asarar nauyi na 24.2% a cikin marasa lafiya, kuma 83% na marasa lafiya sun rasa 15% ko fiye na nauyin jikinsu a makonni 48. Waɗannan sakamakon sun nuna cewa GLP-3 yana da babban yuwuwar asara mai nauyi.
Jiyya na nau'in ciwon sukari na 2: GLP-3 kuma yana nuna wasu yuwuwar a cikin jiyya na nau'in 2 na metabolism. A wasu gwaje-gwajen asibiti, GLP-3 ya nuna raguwar haemoglobin glycated (HbA1c) da asarar nauyi mai dogaro da kashi. Misali, a cikin binciken daya, a cikin marasa lafiya tare da nau'in 2 na metabolism, GLP-3 ya nuna tasirin sarrafa glucose na jini. Idan aka kwatanta da placebo, haemoglobin glycated ya ragu da 1.64% [3] . Bugu da ƙari, a cikin bazuwar, makafi biyu, placebo da aiki-sarrafa daidaitaccen rukuni-rukuni na 2 gwaji, samfuran dabbobi tare da nau'in 2 na metabolism, bayan sun karɓi jiyya na GLP-3, sun nuna raguwa mai yawa a cikin matakan haemoglobin glycated, kuma nauyin jikin su kuma ya ragu ta hanyar dogaro da kashi [4] . Ana iya danganta wannan ga cikakken tasirin maganin akan GLP-1, GCGR, da GIPR, waɗanda ke haɓaka metabolism na glucose da ma'aunin kuzari.
Haɓaka abubuwan haɗari na zuciya da jijiyoyin jini: GLP-3 ba zai iya rage nauyin jiki kawai ba amma kuma yana inganta abubuwan haɗarin zuciya, kamar bayanin martabar lipid na jini da matakan haemoglobin glycated. Wannan yana nuna kusancin haɗin kai na pathophysiological tsakanin kiba da cututtukan zuciya, kuma GLP-3 na iya inganta lafiyar cututtukan zuciya na marasa lafiya masu kiba ta hanyoyi da yawa. Misali, rage marasa HDL-C, apoB, da LDLP matakan na iya rage haɗarin atherosclerosis; Rage matakan haemoglobin glycated na iya inganta sarrafa glucose na jini a cikin marasa lafiya tare da metabolism, ta haka rage haɗarin rikice-rikice na zuciya [3, 5, 6]..
Jiyya na cututtukan hanta maras barasa (NAFLD): GLP-3 sabon labari ne mai karɓar agonist peptide mai karɓa sau uku wanda ke hari ga mai karɓar glucagon (GCGR), mai karɓar insulinotropic polypeptide mai dogaro da glucose (GIPR), da mai karɓar glucagon-like peptide-1 (GLP-1R). Nazarin ya nuna cewa GLP-3 yana da yuwuwar magance cututtukan hanta maras-giya. A cikin binciken daya, an gudanar da gwajin bazuwar, makafi sau biyu, gwajin sarrafa wuribo don makonni 48 akan mahalarta tare da cututtukan hanta mai rauni mai alaƙa da cututtukan hanta da abun ciki mai hanta na ≥10%. Sakamakon ya nuna cewa a cikin makonni 24, matsakaicin matsakaicin dangi canje-canje a cikin kitsen hanta daga asali a cikin mahalarta da aka bi da su tare da nau'i-nau'i daban-daban na GLP-3 (1mg, 4mg, 8mg, da 12mg) sune -42.9%, -57.0%, -81.4%, da -82.4%, bi da bi, yayin da a cikin rukunin placebo ya kasance + 7.3 % . Wannan yana nuna cewa GLP-3 na iya samun tasiri mai mahimmanci na warkewa akan cututtukan hanta mara-giya.
A ƙarshe, a matsayin sabon agonist mai karɓa sau uku, GLP-3 yana nuna babban yuwuwar maganin kiba da cututtukan da ke da alaƙa. Yana iya daidaita metabolism na ɗan adam daga nau'o'i da yawa ta hanyar kunna mai karɓar glucagon, mai karɓar insulinotropic polypeptide mai dogaro da glucose, da mai karɓar glucagon-kamar peptide-1, inganta sarrafa glucose na jini, rage nauyin jiki, da daidaita metabolism na lipid. Bayyanar GLP-3 ya kawo sabbin zaɓuɓɓukan magani ga marasa lafiya masu kiba, nau'in 2 na metabolism, da sauransu. Ana sa ran za a keta iyakokin magungunan gargajiya guda ɗaya na agonist, samar da makami mafi ƙarfi don magance matsalolin matsalolin kiba da cututtukan rayuwa, haɓaka haɓakar ci gaban filayen kiwon lafiya masu alaƙa, haɓaka ingancin rayuwar marasa lafiya, da rage nauyi na likitancin zamantakewa.
Game da Marubuci
Abubuwan da aka ambata a sama duk bincike ne, gyara su kuma Cocer Peptides ne suka haɗa su.
Mawallafin Jaridar Kimiyya
Rosenstock J kwararre ne mai matukar tasiri a fannin likitanci, yana hada gwiwa da cibiyoyi kamar Jami'ar Texas Southwestern Medical Center da Jami'ar Texas Dallas. Hakanan yana gudanar da bincike a cibiyoyi kamar Cibiyar VIGOR ta Kanada da Veloc Clin Res Ctr Med City.
Bincikensa ya shafi ilimin endocrinology da metabolism, tsarin zuciya da jijiyoyin jini da ilimin zuciya, ilimin harhada magunguna, da magungunan gwaji, tare da mai da hankali kan metabolism, kiba, da jiyya masu alaƙa da haɓakar ƙwayoyi. J Rosenstock ya sami nasara mai mahimmanci a cikin maganin asibiti, ana kiransa mai suna Mai Bincike Mai Girma daga 2017 zuwa 2024. Wannan yana nuna babban tasiri da kuma fahimtar aikinsa. Ta hanyar haɗin gwiwa tare da cibiyoyin bincike da yawa, ya sami nasarar fassara sakamakon bincike na asali a cikin aikace-aikacen asibiti, yana amfanar marasa lafiya da cututtuka na rayuwa da na zuciya da jijiyoyin jini da kuma ci gaban kimiyyar likita. An jera Rosenstock J a cikin ambaton ambaton [4].
